Non-beta lactam pharmaceutical manufacturing: what it means and why it matters

When pharmaceutical companies evaluate manufacturing partners, one of the earliest qualifying questions is whether the facility operates as beta lactam or non-beta lactam.

For portfolios outside the antibiotic space, this distinction has direct implications for regulatory compliance, product safety, and manufacturing flexibility.

What beta lactam means in pharmaceutical manufacturing

Beta lactam is a chemical ring structure present in antibiotic families including penicillins, cephalosporins, carbapenems, and monobactams. These compounds present a specific manufacturing challenge: cross-contamination risk.

Beta lactam compounds are potent sensitisers. Trace contamination of a non-antibiotic product can cause serious allergic reactions in sensitive patients. Regulatory authorities therefore require physically separated, dedicated manufacturing with independent air handling, equipment, and personnel flows.

Why dedicated non-beta lactam facilities exist

A non-beta lactam manufacturing facility does not produce beta lactam antibiotic products. This is a fundamental facility classification that shapes what can be manufactured and under what regulatory conditions.

• No beta lactam cross-contamination risk: removing a major supplier-qualification concern for non-antibiotic portfolios.
• Simpler regulatory submissions: export registrations do not require the same beta lactam contamination-risk assessment.
• Manufacturing flexibility: scheduling across a wider range of therapeutic categories without antibiotic-segregation constraints.
• Partner confidence: removing a specific category of manufacturing risk.

Formulation categories

Dedicated non-beta lactam facilities may manufacture a broad range of solid, liquid, and semi-solid dosage forms outside the beta lactam antibiotic space.

• Tablets: immediate-release, film-coated, and modified-release presentations.
• Hard gelatin capsules: formulations for generic and branded-generic portfolios.
• Oral liquids: syrups, suspensions, oral solutions, and emulsions.
• Topicals: ointments, creams, gels, and lotions.

Swift's dedicated facility in Dehradun

Swift Life Sciences operates its composite manufacturing facility at D-1, Sara Industrial Estate Ltd., Rampur, Dehradun as a dedicated non-beta lactam site. It produces tablets, hard gelatin capsules, oral liquids, and topical formulations under WHO-GMP certification and ISO 9001:2015 quality management accreditation.

Explore the facility and certifications or review Swift's portfolio and catalogue.